Lecture 1 - Intro Flashcards
1
Q
Psychiatries 3 Focuses
(Depression as an example)
A
- Diagnosis: Clinically significant distress/impairment
- Treatment: Serotonin enhancing drugs
- Mechanism: Low serotonin in forebrain region.
2
Q
Emil Kraeplin
A
- Argued we can’t make a fundamental distinction between normal and morbid mental states
- Safest foundation is finding pathological anatomy, but this is not always possible with mental illnesses
3
Q
DSM 1
A
- Published in 1952
- Psychoanalysis was the major thearpy
- Neuroses was another prominant theme
- Homosexuality = sociopathic personality disturbance
- Dimensional approach
- In DSM depression was proportional to the actual stress in people’s lives but based on an intuitive weighing
4
Q
Psychoanalysis
A
- Themes: events in early childhood, importance of subconscious (on irrational drives), Neuroses
- Defence mechanisms protect against drives
5
Q
Dimensional Approach
A
- Disorders can happen anywhere on a continuum
- Assessed by evaluating symptom severity
- Also based on frequency in the population
- Used in DSM 1 and 2
6
Q
Removing Homosexuality from DSM
(Hooker experiment)
A
- Gave homosexual/heterosexual men 3 projective personality tests (like Rorschach)
- Experts could not discern between the groups
- Occured in 1974
7
Q
DSM-3
(Problems and Solutions)
A
- Each mental disorder is conceptuatlized as clinically significant which is typically associated with pain, distress or impairment. This impairment is also a disturbance between the individual and society
- Describes a mental trait as a disorder
- Now uses Categorical Approach
Problems
- Low reliability was found in DSM-2 (non-agreement between different clinicians)
- Psychoanalysis is vague/unscientific
Solutions
- Created checklists
- No assessment for symptoms in relation to situational context
- Made situational context part of checklist
8
Q
Categorical Approach
A
- Disorders assessed by meeting/passing criteria checklist
- They predefine what is disorder based on the checklist
- Used in DSM 3-5
9
Q
Lifetime and 12-Month Prevelance of DSM3
(How common, which and solution)
A
- 50% of respondents reported at least 1 lifetime disorder
- 30% reported at least 1 12-month
- Most common were depression, alcohol dependence, social/simple phobia
- Solution: Standardized methods to 1) reduce discrepancies in prevalance rates between similar population surveys and 2) differentiate clinically important disorders from less severe ones
*
10
Q
DSM-4
(and new prevalance rates)
A
- Clinical signifiance added to diagnoses.
- E.g. requires “clinically significant distress or impairment”
- Sets depression as “symptoms cause significant distress or impairment to important areas of functioning”
- Way too broad
- Prevalance: Anxiety (28.8%), mood (20.8%), impulse control (24.8%), substance use (14.6%)
- ANY (46.4%)
- Almost half of college studies had a disorder in the past year
- Depression: Distress is virtually redundant with symptoms of persistent sadness, even in the abscence of major depression
- Doesn’t help to narrow down the population.
11
Q
Depression
A
- Very common, 30-50% lifetime prevalance.
- The bereavement clause
- Removed in the DSM-5 and is considered controversial. Some argue that it undermined rather than increased conceptual valididty and usefulness
*
- Removed in the DSM-5 and is considered controversial. Some argue that it undermined rather than increased conceptual valididty and usefulness
12
Q
DSM-5
A
- Non-disclosure agreements signed for these talks.
- This is a problem, science requires transparency
- They argued, discussions need to be frank so you have to have privacy
13
Q
Controversies in Psychiatry
A
- 1) Psychiatrists were given money from drug companies for years and never reported it
- They were involved in the development of drugs for them.
- 2) Psychiatrists publish selectively on the influence of anti-depressants (94% selected are published, but 50/50 with unpublished)
14
Q
Summary
A
- Research should focus on neurological mechanisms to improve diagnostics and treatmeant
- Diagnostic criteria and treatments are poor.
- Big pharma spinning efficacy of treatments through publication bias, concealing ties with researchers and ghost writing
- Criticisms are not fringe
*